dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Rodriguez Freixinos, Victor |
dc.contributor.author | Fariñas Madrid, Lorena |
dc.contributor.author | Garrido-Castro, Ana Christina |
dc.contributor.author | Nuciforo, Paolo Giovanni |
dc.contributor.author | Vivancos Prellezo, Ana |
dc.contributor.author | Oaknin Benzaquen, Ana Mazaltob |
dc.contributor.author | Villacampa Javierre, Guillermo |
dc.contributor.author | Ruiz Pace, Fiorella |
dc.contributor.author | Dienstmann, Rodrigo |
dc.date.accessioned | 2021-03-17T12:18:20Z |
dc.date.available | 2021-03-17T12:18:20Z |
dc.date.issued | 2019-03-08 |
dc.identifier.citation | Rodriguez-Freixinos V, Ruiz-Pace F, Fariñas-Madrid L, Garrido-Castro AC, Villacampa G, Nuciforo P, et al. Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer. ESMO Open. 2019 Mar 8;4(2):e000444. |
dc.identifier.issn | 2059-7029 |
dc.identifier.uri | https://hdl.handle.net/11351/5768 |
dc.description | Neoplasias ginecológicas; Fracción alélica mutante; PI3K |
dc.language.iso | eng |
dc.publisher | BMJ |
dc.relation.ispartofseries | ESMO Open;4(2) |
dc.rights | Attribution-NonCommercial 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ |
dc.source | Scientia |
dc.subject | Inhibidors enzimàtics |
dc.subject | Aparell genital femení - Càncer |
dc.subject.mesh | Genital Neoplasms, Female |
dc.subject.mesh | /therapy |
dc.subject.mesh | Phosphatidylinositol 3-Kinases |
dc.title | Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1136/esmoopen-2018-000444 |
dc.subject.decs | neoplasias de los genitales femeninos |
dc.subject.decs | /terapia |
dc.subject.decs | fosfatidil inositol 3 cinasas |
dc.relation.publishversion | https://www.esmoopen.com/article/S2059-7029(20)30169-1/fulltext |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Rodriguez-Freixinos V, Fariñas-Madrid L, Oaknin A] Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Gynecological Malignancies Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Ruiz-Pace F, Villacampa G] Oncology Data Science - Prescreening Molecular, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Garrido-Castro AC] Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. [Nuciforo P] Molecular Oncology Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Vivancos A] Cancer Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Dienstmann R] Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Oncology Data Science - Prescreening Molecular, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain |
dc.identifier.pmid | 30962959 |
dc.identifier.wos | 000468581300005 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |